

Molecular network of neuronal autophagy in the pathophysiology and treatment of depression

Jack Jia^{1,2}, Weidong Le³

¹*Sbarro Institute for Cancer Research and Molecular Medicine, Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA*

²*New Jersey Medical Institute, Trenton, NJ, USA*

³*Center for Translational Research on Neurological Disease, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China*

Corresponding author: Weidong Le. E-mail: wdle@sibs.ac.cn

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2015

Major depressive disorder (MDD) is a complicated multifactorial induced disease, characterized by depressed mood, anhedonia, fatigue, and altered cognitive function. Recently, many studies have shown that antidepressants regulate autophagy. In fact, autophagy, a conserved lysosomal degradation pathway, is essential for the central nervous system. Dysregulation of autophagic pathways, such as the mammalian target of rapamycin (mTOR) signaling pathway and the beclin pathway, has been studied in neurodegenerative diseases. However, autophagy in MDD has not been fully studied. Here, we discuss whether the dysregulation of autophagy contributes to the pathophysiology and treatment of MDD and summarize the current evidence that shows the involvement of autophagy in MDD.

Keywords: major depressive disorder; autophagy; mTOR; antidepressant

Introduction

Major depressive disorder (MDD) is a prevalent, heterogeneous illness characterized by depressed mood, anhedonia, low energy or fatigue, and altered cognitive function. Other symptoms, such as sleep and psychomotor disturbances, feelings of guilt, low self-esteem, suicidal tendencies, as well as autonomic and gastrointestinal disturbances, are also often present^[1, 2]. If left untreated, it can be fatal. The lifetime prevalence of MDD is ~17% of the population and results in tremendous secondary costs to society^[3, 4]. The 'gold standard' for depression treatment involves a combination of psychotherapy and medication. Unfortunately, current anti-depressant medications do not help everyone, and both normally take a number of weeks of regular treatment before they begin to have an effect^[5]. Diagnosis of MDD is based on relatively subjective assessments of diverse symptoms representing multiple

endo-phenotypes^[6]. And most current treatments are based on monoamine neurochemical alterations in MDD^[7]. Therefore, knowledge of the mechanism of MDD will help the development of effective treatment. As currently known, MDD is a complicated multifactorial induced disease associated with both genetic and environmental factors, and the detailed molecular mechanisms underlying the pathogenesis remain difficult to elucidate. The pathophysiology of MDD involves complex signaling networks^[8], including alterations of cytokines, monoamine-deficiency in the central nervous system, and dysfunction of the glutamate system. Moreover, MDD is most often related to disturbed neurogenesis, structural and functional alterations of several limbic and cortical regions^[9]. It is also proposed that dysfunction of synaptic plasticity is a basis of the etiology of MDD^[10, 11]. Furthermore, postmortem brain tissues from MDD patients also display increased apoptotic stress and apoptosis-related factors^[12, 13]. Recent studies

indicate that neuronal autophagic signaling pathways are also involved in MDD.

Autophagy is important for most cells in various tissues including the central nervous system; it is sensitive to the accumulation of toxic proteins/damaged organelles^[14]. Therefore, alteration of autophagy during neurodevelopment and synaptic plasticity might cause abnormal development and synaptic malfunction. In addition, impairment of autophagy pathways may lead to the accumulation of pathogenic proteins and damaged organelles, which may finally result in neurological disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD)^[15, 16]. Recently, many antidepressants were found to be involved in the neuronal autophagy signaling pathway. The co-chaperone FKBP5/FKBP51 (FK506 binding protein 5) acting as an antidepressant plays a role in autophagy^[17]. These findings suggest that neuronal autophagy signaling pathways play an important role in MDD, so this review focuses on neuronal autophagy that is involved in MDD and is affected by antidepressants.

Neuronal Autophagy Dysregulation in Neurodegenerative Diseases

Basal Autophagy May Be Beneficial and Required for Normal Function of Neurons

Autophagy is extremely important in maintaining cellular homeostasis, which requires the continuous turnover of nonfunctional proteins and organelles^[18]. Neurons are highly postmitotic, with specialized structures for intercellular communication. Therefore, neuronal integrity is more sensitive to alterations in basal autophagy than that of non-neurons^[14]. Recent findings show that autophagy in neurons is indeed constitutively active, and that autophagosomes accumulate rapidly when their clearance is blocked^[19, 20].

Many studies have shown that autophagy protects neurons under stress conditions. Jeong *et al.* showed that sirtuin 1 (SIRT1) overexpression prevents prion peptide neurotoxicity by inducing autophagy, while preventing autophagy by knock-down of autophagy-related 5 (Atg5) abolishes SIRT1-induced neuroprotection^[21]. Shen *et al.* discovered that neuroautophagy positively regulates

synaptic development, and overexpression of Atg1, a key regulator of autophagy, is sufficient to induce high levels of autophagy and subsequent enhancement of synaptic growth. In contrast, reducing autophagy results in the reduction of synapse size^[22]. Moreover, the autophagosomal marker LC3-II and Akt and mammalian target of rapamycin (mTOR) dephosphorylation have a time-course coincident with degradation of the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor GluR1 in neurons, which indicates that autophagy is a positive regulator of N-methyl-D-aspartate receptor (NMDAR)-dependent synaptic plasticity^[23]. Neuronal autophagy may play important roles in the structural refinement of neurite growth, neuronal differentiation, synaptic growth, or synaptic plasticity, which ensures the formation of appropriate neuronal connections and their functions^[24, 25].

Aberrant Autophagy Leads to Neurodegenerative Diseases, Including Depression

Dysregulation of autophagy might cause a cellular traffic-jam during neuronal development and synaptic plasticity, leading to neurodevelopmental disorders; it also might lead to the accumulation of misfolded protein aggregates and damaged organelles, leading to neuronal dysfunction and even death. Disruption of autophagy after spinal cord injury may contribute to endoplasmic reticulum-stress-induced neuronal apoptosis^[26]. Neuron-specific knockout of the key autophagic gene Atg5 or Atg7 leads to accumulation of intracellular protein aggregates and neuronal death^[19, 20].

Autophagy-lysosome defects occur early in the pathogenesis of AD and have been proposed to be a significant contributor to the disease process^[27]. Nixon *et al.* provided evidence from electron microscopy that autophagy is extensively involved in the neurodegenerative process in AD^[28]. And the transport of autophagic vacuoles and their maturation to lysosomes might be impaired in AD^[29].

Autophagy of mitochondria can be regulated by parkin, PINK1 and DJ-1, and importantly, mutations in these proteins are thought to cause familial PD^[30]. Xilouri *et al.* showed that α -synuclein, a major constituent of Lewy bodies, is degraded by autophagy in PD^[31]. And recently, researchers have established an essential link between mitochondrial autophagy impairment and dopamine neuron degeneration in an *in vivo* model based on genetic deletion of either parkin or PINK1 (known PD genes)^[32].

An autophagy defect has also been suggested by genetic studies of amyotrophic lateral sclerosis (ALS) and frontotemporal lobe dementia (FTD). For instance, mutations in UBQLN2 and SQSTM1/p62 have been reported in ALS and FTD^[33-35]. In fact, UBQLNs are present in autophagosomes and bind LC3 in a complex while SQSTM1/p62 binds ubiquitinated proteins and LC3^[36, 37]. Besides, evidence of direct alteration of the autophagic pathway, bypassing mTOR modulation has been shown in epileptogenesis^[38]. As for depression, increased autophagosomal marker LC3-II has been reported in a cellular model of chemically-induced long-term depression (LTD)^[18].

Interestingly, in the parkinsonian mimetic 6-hydroxydopamine (6-OHDA) model, the 6-OHDA-induced apoptosis is prevented by treatment with the early-phase inhibitor of autophagy, 3-methyladenine, but the late-phase inhibitor of autophagy, bafilomycin A1, aggravates this apoptosis^[39]. In fact, most evidence points to autophagy as a protective process in neurons, but other studies also provide genetic and cellular evidence that otherwise argues for a role of autophagy in promoting neuronal death^[40]. Autophagy might show a Janus face, too much or not enough would lead to disorders like neurodegenerative diseases^[41].

Autophagy-Related Pathways in Depression

Dysregulation of the autophagic pathway in neurons may result in depression^[42]. Autophagy is regulated by intracellular and extracellular signals *via* at least three pathways: (1) The mTOR-dependent pathway: the Atg1/unc-51-like kinase complex acts downstream of mTOR complex 1 (mTORC1); (2) the PI3K/beclin1 pathway; and (3) the Ca²⁺ pathway^[43]. mTORC1 integrates nutrients, energy, growth factors, and amino-acid signaling; once activated, mTORC1 inhibits autophagy by acting on the Atg1 kinase complex, while the beclin complex positively regulates autophagy^[44, 45]. It is now well established that Ca²⁺ is a regulator of autophagy, while it is still unclear whether Ca²⁺ is a positive or a negative regulator^[46].

The PI3K-Akt-mTOR pathway is related to depression^[47]. Decreased AKT1/mTOR mRNA expression has been reported in short-term bipolar disorder^[48]. A recent study showed that neuronal stimulation induces NMDAR-dependent autophagy through the PI3K-Akt-mTOR pathway

in a cellular model of LTD^[25]. Simultaneously, metabotropic glutamate receptor (mGluR) activation results in increased PI3K-mTOR signaling and activation of protein synthesis near synapses in a mouse model of LTD^[25]. And inhibition of protein synthesis or mTOR signaling blocks mGluR-dependent LTD^[49]. In fact, mTOR signaling lies at the crossroads of multiple signals involved in protein synthesis and impairment of autophagy during neurodegeneration^[50, 51]. Activation of mTOR has been functionally linked with local protein synthesis in synapses, resulting in the production of proteins required for the formation, maturation, and function of new spine synapses^[50]. In the meantime, mTORC1 inhibits autophagy, an essential protein-degradation and recycling system^[52]; for example, PI3K-Akt-mTOR is associated with autophagy impairment and is impaired in mild cognitive impairment and AD^[53]. mTOR regulates both neuroprotective (*via* autophagy) and neuroregenerative (*via* protein synthesis) functions in various diseases of the central nervous system^[42].

Brain-derived neurotrophic factor (BDNF) plays an essential role in neuronal plasticity, and downregulation of its expression/function is reproduced in a variety of animal models of MDD^[54]. Indeed, the neuroprotective effect of BDNF not only prevents apoptosis by inhibiting caspase activation but also promotes neuron survival through modulation of autophagy^[55]. And BDNF can be mediated by autophagy through the PI3K-Akt-mTOR pathway^[56]. These results also suggest that autophagy plays an important role in MDD.

In addition, Cummings *et al.* showed that the minimal requirements for inducing LTD involve simply a transient influx of Ca²⁺ into the postsynaptic cell *via* either NMDARs or voltage-dependent Ca²⁺ channels^[57].

We assume that cellular stress in the form of reactive oxygen species or other factors causes proteins to misfold and aggregate. Under normal conditions, this would in turn diminish or overwhelm degradation *via* the autophagy or ubiquitin-proteasome system. However, with autophagy impairment, cells would be unable to clear aggregates and damaged organelles. And additional mitochondrial dysfunction, excitotoxicity, and pore formation lead to increased intracellular Ca²⁺ levels, ultimately resulting in necrosis and apoptosis^[58]. But excessive autophagy also induces apoptosis^[59]. In fact, injury and apoptosis of

hippocampal tissue is the reason for MDD^[60]. From this point of view, autophagy would be an accomplice of MDD (Fig. 1).

Antidepressants and Autophagy

Beyond their impact on monoaminergic neurotransmission, recent reports have evidenced that many antidepressants affect autophagy pathways in the process of anti-depression^[17, 61]. Several studies have demonstrated that cellular autophagy markers are upregulated upon treatment with antidepressants^[62]. Many antidepressants like sertraline activate mTOR. However, antidepressant activity of rapamycin (an mTOR inhibitor) has also been reported in an animal model^[63]. Moreover, autophagic markers, such as beclin1, are increased following antidepressant treatment in mouse brain^[64]. Autophagy might be a double-edged sword in MDD, which may be the reason why some MDD patients remain resistant to certain antidepressant medications.

Antidepressants Affect the Autophagic Pathway

The antidepressant drug amitriptyline (AMI) and the

selective serotonin re-uptake inhibitor citalopram (CIT) have been reported to increase the expression of the autophagic markers LC3-II and beclin1, but venlafaxine fails to exert these effects^[65]. AMI- and CIT-induced autophagy is functional in terms of autophagic flux, and is partially mediated by class III PI3K- and ROS-dependent pathways^[62]. FKBP51 can synergize with antidepressants by binding beclin1, changing its phosphorylation and enhancing markers of autophagy and autophagic flux as well as triggering autophagic pathways^[17]. Chronic paroxetine treatment of a depression-relevant stress model revealed that the physiological effects of antidepressants on behavior and autophagic markers depend on FKBP51^[64]. Trehalose may have antidepressant-like properties through its enhancement of autophagy^[66]. Lithium, which has been used for several decades to treat manic-depressive illness (bipolar affective disorder), induces autophagy, thereby promoting the clearance of mutant huntingtin and alpha-synucleins from experimental systems^[67]. Thus some but not all antidepressants affect autophagy.




Fig. 1. Possible involvement of autophagy in the pathogenesis of MDD.

Autophagy Is a Potential Mechanism of Antidepressant Action

Antidepressants are commonly used in the treatment of cancer patients with depression, and the underlying mechanisms are also related to inducing autophagy. Elevated levels of the autophagic protein beclin-1 and the cellular redistribution of the marker LC3 have been found in C6 glioma cells treated with the antidepressant desipramine (DMI), which induces autophagic cell death by the formation of autophagosomes^[61]. Moreover, activation of the PI3K-AKT-mTOR pathway, which is considered to be a negative regulator of autophagy, is also inhibited by DMI. Furthermore, DMI activates PERK-eIF2 α and ATF6 of the endoplasmic reticulum stress pathway to induce autophagy in C6 glioma cells^[61]. As another example, the tricyclic antidepressant imipramine stimulates the progression of autophagy, and exerts antitumor effects on PTEN-null U-87MG human glioma cells by inhibiting PI3K-Akt-mTOR signaling and by inducing autophagic cell death^[68]. The antidepressants maprotiline and fluoxetine, which are novel pro-autophagic agents, induce autophagic programmed cell death (PCD) in the chemoresistant Burkitt's lymphoma (BL) cell line DG-75; this does not involve caspases, DNA fragmentation, or PARP cleavage, but is associated with the development of cytoplasmic vacuoles, all consistent with an autophagic mode of PCD^[69]. Therefore, autophagy-initiating mechanisms should be considered as a pharmacological target to improve the treatment of depression.

Antidepressants and the mTOR-Dependent Signaling Pathway

The classic antidepressant drugs inhibit the PI3K-Akt-mTOR signaling pathway^[68]. Fluoxetine, an antidepressant that inhibits the reuptake of serotonin in the central nervous system, promotes neurogenesis and improves the survival rate of neurons. A further study suggested that the improvement of neuron survival is achieved by upregulated expression of the phosphorylated AKT protein, which is a key factor in the PI3K-Akt-mTOR signaling pathway^[70]. Another study showed novel *in vitro* evidence that some antidepressant drugs promote dendritic outgrowth and increase synaptic protein levels through mTOR signaling^[71]. Warren *et al.* demonstrated that administration of fluoxetine in combination with methylphenidate induces mTOR activity in rats^[72]. A rapid antidepressant and nonselective NMDAR

antagonist, ketamine, activates the mTOR signaling pathway, leading to increased synaptic proteins in the rat prefrontal cortex^[73].

In fact, most previous reports focused on the mTOR synaptogenesis by antidepressants^[74]. Probably, neuronal autophagy-related mTOR signaling pathways could also explain the mechanism of antidepressant function, for mTOR signaling is at the crossroads between protein synthesis and impairment of autophagy in neurodegeneration^[50, 51]. However, more studies are definitely needed.

Antidepressants and the mTOR-Independent Pathway

Besides, some antidepressant drugs seem to act *via* an mTOR-independent pathway to affect autophagy. For example, autophagy triggered by AMI and CIT is partially mediated by beclin pathways since 3-methyladenine slightly diminishes the effects of AMI. The antidepressant maprotiline has been shown to inhibit dendritic γ -aminobutyric acid- and NMDA-induced increases in Ca²⁺ in primary cultured rat cortical neurons^[75] and in human prostate cancer cells^[76]. Further, calcium channel blockade affects the processes related to antidepressant-induced changes in the crosstalk between α 1- and β -adrenergic receptors^[77]. In fact, it is now well established that intracellular Ca²⁺ is one of the regulators of autophagy^[46]. All these results showed that many antidepressants are involved in autophagy *via* diverse pathways to synergize with antidepressant action. However, more detailed studies are needed to characterize the autophagic pathways in depression and their participation in antidepressant mechanisms^[42].

Conclusion

In summary, MDD is one of the most prevalent debilitating public health problems worldwide. The current review summarized and discussed the possible involvement of neuronal autophagy in MDD. Although the molecular mechanisms underlying MDD are still largely unclear, we proposed that neuronal autophagy signaling network is also implicated in the pathogenesis of MDD and the mechanisms of some antidepressant actions. Further understanding of neuronal autophagy regulation in MDD is expected to contribute to the development of therapeutic interventions in MDD.

Received date: 2015-04-30; Accepted date: 2015-07-17

REFERENCES

- [1] Eshel N, Roiser JP. Reward and punishment processing in depression. *Biol Psychiatry* 2010, 68: 118–124.
- [2] Ito M. Long-term depression. *Annu Rev Neurosci* 1989, 12: 85–102.
- [3] Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005, 62: 617–627.
- [4] Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. *Int J Methods Psychiatr Res* 2003, 12: 22–33.
- [5] Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. *J Occup Environ Med* 2008, 50: 428–436.
- [6] Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. *Neuropsychopharmacology* 2011, 36: 2375–2394.
- [7] Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, *et al.* Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. *Arch Gen Psychiatry* 2006, 63: 1209–1216.
- [8] Villanueva R. Neurobiology of major depressive disorder. *Neural Plast* 2013, 2013: 873278.
- [9] Hasler G. Pathophysiology of depression: do we have any solid evidence. *World Psychiatry* 2010, 9: 155–161.
- [10] Kuhn M, Höger N, Feige B, Blechert J, Normann C, Nissen C. Fear Extinction as a model for synaptic plasticity in major depressive disorder. *PLoS ONE* 2014, 9: e115280.
- [11] Wainwright SR, Galea LA. The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus. *Neural Plast* 2013, 2013: 805497.
- [12] Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, *et al.* Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. *Mol Psychiatry* 2011, 16: 751–762.
- [13] Miguel-Hidalgo JJ, Whittom A, Villarreal A, Soni M, Meshram A, Pickett JC, *et al.* Apoptosis-related proteins and proliferation markers in the orbitofrontal cortex in major depressive disorder. *J Affect Disord* 2014, 158: 62–70.
- [14] Nikolettou V, Papandreou ME, Tavernarakis N. Autophagy in the physiology and pathology of the central nervous system. *Cell Death Differ* 2015, 22: 398–407.
- [15] Takacs-Vellai K, Bayci A, Vellai T. Autophagy in neuronal cell loss: a road to death. *Bioessays* 2006, 28: 1126–1131.
- [16] Nixon RA, Yang DS. Autophagy and neuronal cell death in neurological disorders. *Cold Spring Harb Perspect Biol* 2012, 4.
- [17] Gassen NC, Hartmann J, Schmidt MV, Rein T. FKBP5/FKBP51 enhances autophagy to synergize with antidepressant action. *Autophagy* 2015, 11: 578–580.
- [18] Shehata M, Matsumura H, Okubo-Suzuki R, Ohkawa N, Inokuchi K. Neuronal stimulation induces autophagy in hippocampal neurons that is involved in AMPA receptor degradation after chemical long-term depression. *J Neurosci* 2012, 32: 10413–10422.
- [19] Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, *et al.* Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* 2006, 441: 885–889.
- [20] Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, *et al.* Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 2006, 441: 880–884.
- [21] Jeong JK, Moon MH, Lee YJ, Seol JW, Park SY. Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity. *Neurobiol Aging* 2013, 34: 146–156.
- [22] Shen W, Ganetzky B. Autophagy promotes synapse development in *Drosophila*. *J Cell Biol* 2009, 187: 71–79.
- [23] Bateup HS, Takasaki KT, Saulnier JL, Deneff CL, Sabatini BL. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. *J Neurosci* 2011, 31: 8862–8869.
- [24] Damme M, Suntuio T, Saftig P, Eskelinen EL. Autophagy in neuronal cells: general principles and physiological and pathological functions. *Acta Neuropathol* 2015, 129: 337–362.
- [25] Lee KM, Hwang SK, Lee JA. Neuronal autophagy and neurodevelopmental disorders. *Exp Neurobiol* 2013, 22: 133–142.
- [26] Liu S, Sarkar C, Dinizo M, Faden AI, Koh EY, Lipinski MM, *et al.* Disrupted autophagy after spinal cord injury is associated with ER stress and neuronal cell death. *Cell Death Dis* 2015, 6: e1582.
- [27] Zare-Shahabadi A, Masliah E, Johnson GV, Rezaei N. Autophagy in Alzheimer's disease. *Rev Neurosci* 2015.
- [28] Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, *et al.* Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. *J Neuropathol Exp Neurol* 2005, 64: 113–122.
- [29] Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, *et al.* Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. *J Cell Biol* 2005, 171: 87–98.
- [30] Giordano S, Darley-Usmar V, Zhang J. Autophagy as an

- essential cellular antioxidant pathway in neurodegenerative disease. *Redox Biol* 2014, 2: 82-90.
- [31] Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. *PLoS One* 2009, 4: e5515.
- [32] Chen L, Xie Z, Turkson S, Zhuang X. A53T human alpha-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. *J Neurosci* 2015, 35: 890–905.
- [33] Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, *et al.* Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. *Nature* 2011, 477: 211–215.
- [34] Fecto F, Siddique T. UBQLN2/P62 cellular recycling pathways in amyotrophic lateral sclerosis and frontotemporal dementia. *Muscle Nerve* 2012, 45: 157–162.
- [35] Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, *et al.* SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. *Arch Neurol* 2011, 68: 1440–1446.
- [36] Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, *et al.* p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J Biol Chem* 2007, 282: 24131–24145.
- [37] Rothenberg C, Srinivasan D, Mah L, Kaushik S, Peterhoff CM, Ugolino J, *et al.* Ubiquitin functions in autophagy and is degraded by chaperone-mediated autophagy. *Hum Mol Genet* 2010, 19: 3219–3232.
- [38] Giorgi FS, Biagioni F, Lenzi P, Frati A, Fornai F. The role of autophagy in epileptogenesis and in epilepsy-induced neuronal alterations. *J Neural Transm* 2014.
- [39] In S, Hong CW, Choi B, Jang BG, Kim MJ. Inhibition of mitochondrial clearance and Cu/Zn-SOD activity enhance 6-hydroxydopamine-induced neuronal apoptosis. *Mol Neurobiol* 2015.
- [40] Son JH, Shim JH, Kim KH, Ha JY, Han JY. Neuronal autophagy and neurodegenerative diseases. *Exp Mol Med* 2012, 44: 89–98.
- [41] Ren J, Taegtmeyer H. Too much or not enough of a good thing - The Janus faces of autophagy in cardiac fuel and protein homeostasis. *J Mol Cell Cardiol* 2015, 84: 223–226.
- [42] Abelaira HM, Reus GZ, Neotti MV, Quevedo J. The role of mTOR in depression and antidepressant responses. *Life Sci* 2014, 101: 10–14.
- [43] Polajnar M, Zerovnik E. Impaired autophagy: a link between neurodegenerative and neuropsychiatric diseases. *J Cell Mol Med* 2014, 18: 1705–1711.
- [44] Zeng M, Zhou JN. Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells. *Cell Signal* 2008, 20: 659–665.
- [45] Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. *Biochimie* 2008, 90: 313–323.
- [46] Decuypere JP, Bultynck G, Parys JB. A dual role for Ca(2+) in autophagy regulation. *Cell Calcium* 2011, 50: 242–250.
- [47] Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, *et al.* The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2011, 35: 1774–1779.
- [48] Machado-Vieira R, Zanetti MV, Teixeira AL, Uno M, Valiengo LL, Soeiro-de-Souza MG, *et al.* Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. *Eur Neuropsychopharmacol* 2015, 25: 468–473.
- [49] Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. *Nat Rev Neurosci* 2004, 5: 173–183.
- [50] Hoeffler CA, Klann E. mTOR Signaling: At the Crossroads of Plasticity, Memory, and Disease. *Trends Neurosci* 2010, 33: 67.
- [51] Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? *Aging (Albany NY)* 2009, 1: 586–597.
- [52] Wong YC, Holzbaur EL. Autophagosome dynamics in neurodegeneration at a glance. *J Cell Sci* 2015, 128: 1259–1267.
- [53] Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, *et al.* Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnesic mild cognitive impairment and late-stage AD. *J Neurochem* 2015, 133: 739–749.
- [54] Numakawa T, Richards M, Nakajima S, Adachi N, Furuta M, Odaka H, *et al.* The role of brain-derived neurotrophic factor in comorbid depression: possible linkage with steroid hormones, cytokines, and nutrition. *Frontiers in psychiatry* 2014, 5: 136.
- [55] Smith E, Prieto G, Tong L, Sears-Kraxberger I, Rice J, Steward O, *et al.* Rapamycin and interleukin-1 β impair brain-derived neurotrophic factor-dependent neuron survival by modulating autophagy. *J Biol Chem* 2014, 289: 20615–20629.
- [56] Chen A, Xiong L, Tong Y, Mao M. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway. *Mol Med Rep* 2013, 8: 1011–1016.
- [57] Cummings JA, Mulkey RM, Nicoll RA, Malenka RC. Ca²⁺ signaling requirements for long-term depression in the hippocampus. *Neuron* 1996, 16: 825–833.
- [58] Rikiishi H. Novel insights into the interplay between apoptosis

- and autophagy. *Int J Cell Biol* 2012, 2012: 317645.
- [59] Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. *Nat Rev Mol Cell Biol* 2014, 15: 81–94.
- [60] Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, *et al.* Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. *Mol Psychiatry* 2011, 16: 751–762.
- [61] Ma J, Hou LN, Rong ZX, Liang P, Fang C, Li HF, *et al.* Antidepressant desipramine leads to C6 glioma cell autophagy: implication for the adjuvant therapy of cancer. *Anticancer Agents Med Chem* 2013, 13: 254–260.
- [62] Zschocke J, Rein T. Antidepressants encounter autophagy in neural cells. *Autophagy* 2011, 7: 1247–1248.
- [63] Cleary C, Linde JA, Hiscock KM, Hadas I, Belmaker RH, Agam G, *et al.* Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders. *Brain Res Bull* 2008, 76: 469–473.
- [64] Gassen NC, Hartmann J, Zschocke J, Stepan J, Hafner K, Zellner A, *et al.* Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans. *PLoS Med* 2014, 11: e1001755.
- [65] Zschocke J, Zimmermann N, Berning B, Ganai V, Holsboer F, Rein T. Antidepressant drugs diversely affect autophagy pathways in astrocytes and neurons—dissociation from cholesterol homeostasis. *Neuropsychopharmacology* 2011, 36: 1754–1768.
- [66] Kara NZ, Toker L, Agam G, Anderson GW, Belmaker RH, Einat H. Trehalose induced antidepressant-like effects and autophagy enhancement in mice. *Psychopharmacology (Berl)* 2013, 229: 367–375.
- [67] Heiseke A, Aguib Y, Riemer C, Baier M, Schätzl H. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. *J Neurochem* 2009, 109: 25–34.
- [68] Jeon SH, Kim SH, Kim Y, Kim YS, Lim Y, Lee YH, *et al.* The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. *Biochem Biophys Res Commun* 2011, 413: 311–317.
- [69] Cloonan SM, Williams DC. The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma. *Int J Cancer* 2011, 128: 1712–1723.
- [70] Kitagishi Y, Kobayashi M, Kikuta K, Matsuda S. Roles of PI3K/AKT/GSK3/mTOR pathway in cell signaling of mental illnesses. *Depress Res Treat* 2012, 2012: 752563.
- [71] Park SW, Lee JG, Seo MK, Lee CH, Cho HY, Lee BJ, *et al.* Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons. *Int J Neuropsychopharmacol* 2014, 17: 1831–1846.
- [72] Warren BL, Iniguez SD, Alcantara LF, Wright KN, Parise EM, Weakley SK, *et al.* Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood. *J Neurosci* 2011, 31: 10347–10358.
- [73] Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, *et al.* mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science* 2010, 329: 959–964.
- [74] Duman RS, Li N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. *Philos Trans R Soc Lond B Biol Sci* 2012, 367: 2475–2484.
- [75] Takebayashi M, Kagaya A, Inagaki M, Kozuru T, Jitsuiki H, Kurata K, *et al.* Effects of antidepressants on gamma-aminobutyric acid- and N-methyl-D-aspartate-induced intracellular Ca(2+) concentration increases in primary cultured rat cortical neurons. *Neuropsychobiology* 2000, 42: 120–126.
- [76] Hsu SS, Chen WC, Lo YK, Cheng JS, Yeh JH, Cheng HH, *et al.* Effect of the antidepressant maprotiline on Ca2+ movement and proliferation in human prostate cancer cells. *Clin Exp Pharmacol Physiol* 2004, 31: 444–449.
- [77] Nalepa I, Kowalska M, Kreiner G, Vetulani J. Does Ca2+ channel blockade modulate the antidepressant-induced changes in mechanisms of adrenergic transduction? *J Neural Transm* 1997, 104: 535–547.